URGN vs. VNDA, XOMA, ME, NATR, VTYX, CRMD, RANI, AQST, MRSN, and ATAI
Should you be buying UroGen Pharma stock or one of its competitors? The main competitors of UroGen Pharma include Vanda Pharmaceuticals (VNDA), XOMA (XOMA), 23andMe (ME), Nature's Sunshine Products (NATR), Ventyx Biosciences (VTYX), CorMedix (CRMD), Rani Therapeutics (RANI), Aquestive Therapeutics (AQST), Mersana Therapeutics (MRSN), and Atai Life Sciences (ATAI). These companies are all part of the "pharmaceutical preparations" industry.
Vanda Pharmaceuticals (NASDAQ:VNDA) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations, community ranking and profitability.
In the previous week, UroGen Pharma had 17 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 22 mentions for UroGen Pharma and 5 mentions for Vanda Pharmaceuticals. UroGen Pharma's average media sentiment score of 0.32 beat Vanda Pharmaceuticals' score of -0.19 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.
88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 91.3% of UroGen Pharma shares are held by institutional investors. 7.7% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 11.1% of UroGen Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Vanda Pharmaceuticals has a net margin of -2.75% compared to Vanda Pharmaceuticals' net margin of -123.74%. Vanda Pharmaceuticals' return on equity of 0.00% beat UroGen Pharma's return on equity.
Vanda Pharmaceuticals has higher revenue and earnings than UroGen Pharma. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.
UroGen Pharma has a consensus target price of $46.00, suggesting a potential upside of 248.22%. Given Vanda Pharmaceuticals' higher probable upside, analysts clearly believe UroGen Pharma is more favorable than Vanda Pharmaceuticals.
Vanda Pharmaceuticals received 180 more outperform votes than UroGen Pharma when rated by MarketBeat users. However, 73.29% of users gave UroGen Pharma an outperform vote while only 68.55% of users gave Vanda Pharmaceuticals an outperform vote.
Vanda Pharmaceuticals has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, UroGen Pharma has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.
Summary
UroGen Pharma beats Vanda Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get UroGen Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding URGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
UroGen Pharma Competitors List
Related Companies and Tools
